Therefore, the cIMPACT-NOW Update 3 provided diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma WHO Grade IV,” and recommended that histologic grade II and III IDH-wildtype diffuse astrocytic glioma that contain a high level of EGFR amplification, the combination of whole chromosome 7 gain and whole chromosome 10 loss, or TERT promoter mutations, correspond to WHO grade IV and be referred to as diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV (23). Here, EGFR is linked to glioblastoma.